Paclitaxel is a standard chemotherapy drug used to treat ovarian cancer. However, in many patients, the cancer persists or returns. The purpose of this study is to find the highest dose of an investigational drug called MEK162 that can be given in combination with paclitaxel in women with ovarian, fallopian tube, or primary peritoneal cancer that has returned despite therapy that included a platinum-containing drug.
MEK162 works by inhibiting a protein called MEK1/2, which can fuel cancer cell growth. It is taken orally (by mouth).